Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril

Richard A Preston, Alberto Alonso, Darlene Panzitta, Paul Zhang, Adel H. Karara

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background: Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP/17β-estradiol (DRSP/E2). We investigated the additive effect of DRSP/E2 versus placebo on 24-h ambulatory blood pressure (BP) in postmenopausal women with hypertension treated with enalapril maleate (ENA). Methods: This was a double-blind, randomized, two-parallel group trial. Twenty-four nonsmoking postmenopausal women receiving 10 mg of ENA twice a day before study were randomized to DRSP/E2 + ENA (n = 12) or placebo (P) + ENA (n = 12) for 14 days. Twenty-four-hour ambulatory BP, plasma renin activity, and serum aldosterone were determined at baseline and on day 14. Results: Compared to placebo, 24-h mean [SD] BP in the DRSP/E2 + ENA group decreased significantly from baseline (139/80 mm Hg), systolic (-9 [5] mm Hg, P = .014) and diastolic (-5 [4] mm Hg, P = .007). Essentially no change from baseline (139/83 mm Hg) in systolic or diastolic 24-h ambulatory BP were observed in the P + ENA group. Aldosterone (mean [SD]) increased from baseline by 2.6 [4.5] ng/dL in the DRSP/E2 + ENA group, and decreased by 0.3 [5.5] ng/dL in the P + ENA group (P = .08) consistent with an antimineralocorticoid effect. Conclusions: Our results suggest a significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA, consistent with an antimineralocorticoid effect. DRSP/E2, a HRT with antimineralocorticoid effects, could offer a novel potential mechanism for reducing cardiovascular end points in postmenopausal women.

Original languageEnglish
Pages (from-to)816-822
Number of pages7
JournalAmerican Journal of Hypertension
Volume15
Issue number9
DOIs
StatePublished - Sep 1 2002

Fingerprint

Enalapril
Estradiol
Blood Pressure
Aldosterone
Hormone Replacement Therapy
Placebos
Mineralocorticoid Receptor Antagonists
drospirenone
Progestins
Renin
Cardiovascular Diseases
Hypertension

Keywords

  • Aldosterone
  • Aldosterone antagonists
  • Drospirenone
  • Hormone replacement therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril. / Preston, Richard A; Alonso, Alberto; Panzitta, Darlene; Zhang, Paul; Karara, Adel H.

In: American Journal of Hypertension, Vol. 15, No. 9, 01.09.2002, p. 816-822.

Research output: Contribution to journalArticle

Preston, Richard A ; Alonso, Alberto ; Panzitta, Darlene ; Zhang, Paul ; Karara, Adel H. / Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril. In: American Journal of Hypertension. 2002 ; Vol. 15, No. 9. pp. 816-822.
@article{9b5e8a2184dc402ab30bb35d7a388ea7,
title = "Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril",
abstract = "Background: Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP/17β-estradiol (DRSP/E2). We investigated the additive effect of DRSP/E2 versus placebo on 24-h ambulatory blood pressure (BP) in postmenopausal women with hypertension treated with enalapril maleate (ENA). Methods: This was a double-blind, randomized, two-parallel group trial. Twenty-four nonsmoking postmenopausal women receiving 10 mg of ENA twice a day before study were randomized to DRSP/E2 + ENA (n = 12) or placebo (P) + ENA (n = 12) for 14 days. Twenty-four-hour ambulatory BP, plasma renin activity, and serum aldosterone were determined at baseline and on day 14. Results: Compared to placebo, 24-h mean [SD] BP in the DRSP/E2 + ENA group decreased significantly from baseline (139/80 mm Hg), systolic (-9 [5] mm Hg, P = .014) and diastolic (-5 [4] mm Hg, P = .007). Essentially no change from baseline (139/83 mm Hg) in systolic or diastolic 24-h ambulatory BP were observed in the P + ENA group. Aldosterone (mean [SD]) increased from baseline by 2.6 [4.5] ng/dL in the DRSP/E2 + ENA group, and decreased by 0.3 [5.5] ng/dL in the P + ENA group (P = .08) consistent with an antimineralocorticoid effect. Conclusions: Our results suggest a significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA, consistent with an antimineralocorticoid effect. DRSP/E2, a HRT with antimineralocorticoid effects, could offer a novel potential mechanism for reducing cardiovascular end points in postmenopausal women.",
keywords = "Aldosterone, Aldosterone antagonists, Drospirenone, Hormone replacement therapy",
author = "Preston, {Richard A} and Alberto Alonso and Darlene Panzitta and Paul Zhang and Karara, {Adel H.}",
year = "2002",
month = "9",
day = "1",
doi = "10.1016/S0895-7061(02)02980-1",
language = "English",
volume = "15",
pages = "816--822",
journal = "Journal of clinical hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril

AU - Preston, Richard A

AU - Alonso, Alberto

AU - Panzitta, Darlene

AU - Zhang, Paul

AU - Karara, Adel H.

PY - 2002/9/1

Y1 - 2002/9/1

N2 - Background: Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP/17β-estradiol (DRSP/E2). We investigated the additive effect of DRSP/E2 versus placebo on 24-h ambulatory blood pressure (BP) in postmenopausal women with hypertension treated with enalapril maleate (ENA). Methods: This was a double-blind, randomized, two-parallel group trial. Twenty-four nonsmoking postmenopausal women receiving 10 mg of ENA twice a day before study were randomized to DRSP/E2 + ENA (n = 12) or placebo (P) + ENA (n = 12) for 14 days. Twenty-four-hour ambulatory BP, plasma renin activity, and serum aldosterone were determined at baseline and on day 14. Results: Compared to placebo, 24-h mean [SD] BP in the DRSP/E2 + ENA group decreased significantly from baseline (139/80 mm Hg), systolic (-9 [5] mm Hg, P = .014) and diastolic (-5 [4] mm Hg, P = .007). Essentially no change from baseline (139/83 mm Hg) in systolic or diastolic 24-h ambulatory BP were observed in the P + ENA group. Aldosterone (mean [SD]) increased from baseline by 2.6 [4.5] ng/dL in the DRSP/E2 + ENA group, and decreased by 0.3 [5.5] ng/dL in the P + ENA group (P = .08) consistent with an antimineralocorticoid effect. Conclusions: Our results suggest a significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA, consistent with an antimineralocorticoid effect. DRSP/E2, a HRT with antimineralocorticoid effects, could offer a novel potential mechanism for reducing cardiovascular end points in postmenopausal women.

AB - Background: Aldosterone has been implicated in the pathogenesis of progressive cardiovascular disease. Drospirenone (DRSP) is a novel progestin with aldosterone receptor antagonist activity developed for hormone replacement therapy (HRT) as DRSP/17β-estradiol (DRSP/E2). We investigated the additive effect of DRSP/E2 versus placebo on 24-h ambulatory blood pressure (BP) in postmenopausal women with hypertension treated with enalapril maleate (ENA). Methods: This was a double-blind, randomized, two-parallel group trial. Twenty-four nonsmoking postmenopausal women receiving 10 mg of ENA twice a day before study were randomized to DRSP/E2 + ENA (n = 12) or placebo (P) + ENA (n = 12) for 14 days. Twenty-four-hour ambulatory BP, plasma renin activity, and serum aldosterone were determined at baseline and on day 14. Results: Compared to placebo, 24-h mean [SD] BP in the DRSP/E2 + ENA group decreased significantly from baseline (139/80 mm Hg), systolic (-9 [5] mm Hg, P = .014) and diastolic (-5 [4] mm Hg, P = .007). Essentially no change from baseline (139/83 mm Hg) in systolic or diastolic 24-h ambulatory BP were observed in the P + ENA group. Aldosterone (mean [SD]) increased from baseline by 2.6 [4.5] ng/dL in the DRSP/E2 + ENA group, and decreased by 0.3 [5.5] ng/dL in the P + ENA group (P = .08) consistent with an antimineralocorticoid effect. Conclusions: Our results suggest a significant additive BP-lowering effect of DRSP/E2 on both systolic and diastolic BP in hypertensive postmenopausal women receiving ENA, consistent with an antimineralocorticoid effect. DRSP/E2, a HRT with antimineralocorticoid effects, could offer a novel potential mechanism for reducing cardiovascular end points in postmenopausal women.

KW - Aldosterone

KW - Aldosterone antagonists

KW - Drospirenone

KW - Hormone replacement therapy

UR - http://www.scopus.com/inward/record.url?scp=0036724411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036724411&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(02)02980-1

DO - 10.1016/S0895-7061(02)02980-1

M3 - Article

C2 - 12219878

AN - SCOPUS:0036724411

VL - 15

SP - 816

EP - 822

JO - Journal of clinical hypertension

JF - Journal of clinical hypertension

SN - 0895-7061

IS - 9

ER -